Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Utah Medical Products (UTMD) EPS (Weighted Average and Diluted) (2016 - 2025)

Utah Medical Products (UTMD) has 16 years of EPS (Weighted Average and Diluted) data on record, last reported at $0.82 in Q3 2025.

  • For Q3 2025, EPS (Weighted Average and Diluted) fell 20.39% year-over-year to $0.82; the TTM value through Sep 2025 reached $3.54, down 17.29%, while the annual FY2024 figure was $3.96, 235.59% up from the prior year.
  • EPS (Weighted Average and Diluted) reached $0.82 in Q3 2025 per UTMD's latest filing, down from $0.94 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $1.18 in Q3 2022 and bottomed at $0.82 in Q3 2025.
  • Average EPS (Weighted Average and Diluted) over 5 years is $1.03, with a median of $1.06 recorded in 2023.
  • Peak YoY movement for EPS (Weighted Average and Diluted): soared 161.11% in 2021, then decreased 27.12% in 2024.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $1.13 in 2021, then grew by 4.42% to $1.18 in 2022, then changed by 0.0% to $1.18 in 2023, then fell by 27.12% to $0.86 in 2024, then dropped by 4.65% to $0.82 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Weighted Average and Diluted) were $0.82 in Q3 2025, $0.94 in Q2 2025, and $0.92 in Q1 2025.